Previous 10 | Next 10 |
2023-05-04 12:22:09 ET Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2023 Earnings Conference Call May 4, 2023 8:30 AM ET Company Participants Christine Lindenboom – Senior Vice President-Investor Relations and Corporate Communication Yvonne Greenstreet – Chi...
2023-05-04 10:49:30 ET Ionis Pharmaceuticals ( NASDAQ: IONS ) traded flat on Thursday after Citi upgraded the developer of RNA-targeted therapeutics to Neutral from Sell following the company's better-than-expected Q1 2023 results. Carlsbad, California-based biotech reported...
2023-05-04 08:04:24 ET Alnylam Pharmaceuticals press release ( NASDAQ: ALNY ): Q1 Non-GAAP EPS of -$1.06 beats by $0.37 . Revenue of $319.29M (+49.7% Y/Y) beats by $6.76M . Reiterated 2023 Financial Guidance, Including Combined Net Product Revenues of $1,200 Mi...
− Achieved First Quarter 2023 Global Net Product Revenues of $276 Million, Representing 48% Year-Over-Year Growth Compared to Q1 2022 – − Reported Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the BofA Securities 2023 Health Care Conference on Wednesday, May 10, 2023 at 1:40 pm PT (4:40 pm ET) at the Encore Hotel in Las Vegas. A l...
2023-05-03 13:37:29 ET Alnylam Pharmaceuticals ( NASDAQ: ALNY ) is scheduled to announce Q1 earnings results on Thursday, May 4th, before market open. The consensus EPS Estimate is -$1.43 (+4.0% Y/Y) and the consensus Revenue Estimate is $312.53M (+46.5% Y/Y). Over the...
– Successfully Met Goals Outlined in MassBio’s Diversity, Equity, and Inclusion (DE&I) Industry Pledge – – New Disclosures of Company’s Impact on Planet—Including Multiyear Data on Scope 1, Scope 2, and Select Scope 3 Greenhouse Gas (GHG) ...
2023-04-26 17:15:43 ET For further details see: Partial clinical hold placed on Alnylam, Regeneron RNAi Alzheimer's candidate
– Single Doses of ALN-APP Demonstrated Dose-Dependent, Rapid and Sustained Reduction of sAPPα and sAPPβ in Cerebrospinal Fluid, with Up to 90% at Highest Dose to Date – – Encouraging Clinical Safety and Tolerability Profile Observed with Single Dosing ...
- Single Doses of ALN-APP Demonstrated Dose-Dependent, Rapid and Sustained Reduction of sAPPα and sAPPβ in Cerebrospinal Fluid, with Up to 90% at Highest Dose to Date - - Encouraging Clinical Safety and Tolerability Profile Observed with Single Dosing to Date - - R...
News, Short Squeeze, Breakout and More Instantly...
Alnylam Pharmaceuticals Inc. Company Name:
ALNY Stock Symbol:
NASDAQ Market:
Alnylam Pharmaceuticals Inc. Website:
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2024 on Thursday, August 1, 2024, before the U.S. financial markets open. Management will provide an update on th...
2024-06-29 16:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...